In Wednesday’s Wall Street session, Abeona Therapeutics Inc (NASDAQ:ABEO) shares traded at $6.56, up 23.77% from the previous session.
ABEO stock price is now 28.23% away from the 50-day moving average and 17.66% away from the 200-day moving average. The market capitalization of the company currently stands at $320.13M.
With the price target of $16, Oppenheimer recently initiated with Outperform rating for Abeona Therapeutics Inc (NASDAQ: ABEO). On July 03, 2024, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $15, while ‘Stifel’ rates the stock as ‘Buy’
In other news, Seshadri Vishwas, Chief Executive Officer sold 25,000 shares of the company’s stock on Mar 31 ’25. The stock was sold for $119,500 at an average price of $4.78. Upon completion of the transaction, the Chief Executive Officer now directly owns 1,355,322 shares in the company, valued at $8.89 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 31 ’25, Officer Seshadri Vishwas bought 25,000 shares of the business’s stock. A total of $119,560 was incurred on buying the stock at an average price of $4.78. A total of 11.64% of the company’s stock is owned by insiders.
During the past 12 months, Abeona Therapeutics Inc has had a low of $3.44 and a high of $6.78. As of last week, the company has a debt-to-equity ratio of 0.52, a current ratio of 6.08, and a quick ratio of 6.08. The fifty day moving average price for ABEO is $5.1158 and a two-hundred day moving average price translates $5.5753 for the stock.
The latest earnings results from Abeona Therapeutics Inc (NASDAQ: ABEO) was released for 2024-12-31.
